93 results on '"Gomis, Roger R."'
Search Results
2. Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy
- Author
-
Linares, Jenniffer, Sallent-Aragay, Anna, Badia-Ramentol, Jordi, Recort-Bascuas, Alba, Méndez, Ana, Manero-Rupérez, Noemí, Re, Daniele Lo, Rivas, Elisa I., Guiu, Marc, Zwick, Melissa, Iglesias, Mar, Martinez-Ciarpaglini, Carolina, Tarazona, Noelia, Varese, Monica, Hernando-Momblona, Xavier, Cañellas-Socias, Adrià, Orrillo, Mayra, Garrido, Marta, Saoudi, Nadia, Elez, Elena, Navarro, Pilar, Tabernero, Josep, Gomis, Roger R., Batlle, Eduard, Pisonero, Jorge, Cervantes, Andres, Montagut, Clara, and Calon, Alexandre
- Published
- 2023
- Full Text
- View/download PDF
3. Design and optimization of oestrogen receptor PROTACs based on 4-hydroxytamoxifen
- Author
-
Loren, Guillem, Espuny, Irene, Llorente, Alicia, Donoghue, Craig, Verdaguer, Xavier, Gomis, Roger R., and Riera, Antoni
- Published
- 2022
- Full Text
- View/download PDF
4. Ecology and evolution of dormant metastasis
- Author
-
Blasco, María Teresa, Espuny, Irene, and Gomis, Roger R.
- Published
- 2022
- Full Text
- View/download PDF
5. Paper-based biosensors for cancer diagnostics
- Author
-
Pereira, Claudia, Parolo, Claudio, Idili, Andrea, Gomis, Roger R., Rodrigues, Lígia, Sales, Goreti, and Merkoçi, Arben
- Published
- 2022
- Full Text
- View/download PDF
6. LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer
- Author
-
Pérez-Núñez, Iván, Rozalén, Catalina, Palomeque, José Ángel, Sangrador, Irene, Dalmau, Mariona, Comerma, Laura, Hernández-Prat, Anna, Casadevall, David, Menendez, Silvia, Liu, Daniel Dan, Shen, Minhong, Berenguer, Jordi, Ruiz, Irene Rius, Peña, Raul, Montañés, José Carlos, Albà, M. Mar, Bonnin, Sarah, Ponomarenko, Julia, Gomis, Roger R., Cejalvo, Juan Miguel, Servitja, Sonia, Marzese, Diego M., Morey, Lluis, Voorwerk, Leonie, Arribas, Joaquín, Bermejo, Begoña, Kok, Marleen, Pusztai, Lajos, Kang, Yibin, Albanell, Joan, and Celià-Terrassa, Toni
- Published
- 2022
- Full Text
- View/download PDF
7. Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors
- Author
-
Rivas, Elisa I., Linares, Jenniffer, Zwick, Melissa, Gómez-Llonin, Andrea, Guiu, Marc, Labernadie, Anna, Badia-Ramentol, Jordi, Lladó, Anna, Bardia, Lídia, Pérez-Núñez, Iván, Martínez-Ciarpaglini, Carolina, Tarazona, Noelia, Sallent-Aragay, Anna, Garrido, Marta, Celià-Terrassa, Toni, Burgués, Octavio, Gomis, Roger R., Albanell, Joan, and Calon, Alexandre
- Published
- 2022
- Full Text
- View/download PDF
8. The PP2A regulator IER5L supports prostate cancer progression.
- Author
-
Crespo, Jana R., Martín-Martín, Natalia, Garcia-Longarte, Saioa, Corres-Mendizabal, Jon, Carlevaris, Onintza, Astobiza, Ianire, Zabala-Letona, Amaia, Guiu, Marc, Azkargorta, Mikel, Gonzalez-Lopez, Monika, Macías-Cámara, Nuria, Doan, Phuong, Elortza, Félix, Mendizabal, Isabel, Westermack, Jukka, Gomis, Roger R., Ercilla, Amaia, and Carracedo, Arkaitz
- Published
- 2024
- Full Text
- View/download PDF
9. Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
- Author
-
Brasó-Maristany, Fara, Griguolo, Gaia, Pascual, Tomás, Paré, Laia, Nuciforo, Paolo, Llombart-Cussac, Antonio, Bermejo, Begoña, Oliveira, Mafalda, Morales, Serafín, Martínez, Noelia, Vidal, Maria, Adamo, Barbara, Martínez, Olga, Pernas, Sonia, López, Rafael, Muñoz, Montserrat, Chic, Núria, Galván, Patricia, Garau, Isabel, Manso, Luis, Alarcón, Jesús, Martínez, Eduardo, Gregorio, Sara, Gomis, Roger R., Villagrasa, Patricia, Cortés, Javier, Ciruelos, Eva, and Prat, Aleix
- Published
- 2020
- Full Text
- View/download PDF
10. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer
- Author
-
Gawrzak, Sylwia, Rinaldi, Lorenzo, Gregorio, Sara, Arenas, Enrique J., Salvador, Fernando, Urosevic, Jelena, Figueras-Puig, Cristina, Rojo, Federico, del Barco Barrantes, Ivan, Cejalvo, Juan Miguel, Palafox, Marta, Guiu, Marc, Berenguer-Llergo, Antonio, Symeonidi, Aikaterini, Bellmunt, Anna, Kalafatovic, Daniela, Arnal-Estapé, Anna, Fernández, Esther, Müllauer, Barbara, Groeneveld, Rianne, Slobodnyuk, Konstantin, Stephan-Otto Attolini, Camille, Saura, Cristina, Arribas, Joaquín, Cortes, Javier, Rovira, Ana, Muñoz, Montse, Lluch, Ana, Serra, Violeta, Albanell, Joan, Prat, Aleix, Nebreda, Angel R., Benitah, Salvador Aznar, and Gomis, Roger R.
- Published
- 2018
- Full Text
- View/download PDF
11. The metabolic co-regulator PGC1α suppresses prostate cancer metastasis
- Author
-
Torrano, Veronica, Valcarcel-Jimenez, Lorea, Cortazar, Ana Rosa, Liu, Xiaojing, Urosevic, Jelena, Castillo-Martin, Mireia, Fernández-Ruiz, Sonia, Morciano, Giampaolo, Caro-Maldonado, Alfredo, Guiu, Marc, Zúñiga-García, Patricia, Graupera, Mariona, Bellmunt, Anna, Pandya, Pahini, Lorente, Mar, Martín-Martín, Natalia, Sutherland, James David, Sanchez-Mosquera, Pilar, Bozal-Basterra, Laura, Zabala-Letona, Amaia, Arruabarrena-Aristorena, Amaia, Berenguer, Antonio, Embade, Nieves, Ugalde-Olano, Aitziber, Lacasa-Viscasillas, Isabel, Loizaga-Iriarte, Ana, Unda-Urzaiz, Miguel, Schultz, Nikolaus, Aransay, Ana Maria, Sanz-Moreno, Victoria, Barrio, Rosa, Velasco, Guillermo, Pinton, Paolo, Cordon-Cardo, Carlos, Locasale, Jason W., Gomis, Roger R., and Carracedo, Arkaitz
- Published
- 2016
- Full Text
- View/download PDF
12. Understanding the molecular mechanisms driving metastasis
- Author
-
Massagué, Joan, Batlle, Eduard, and Gomis, Roger R.
- Published
- 2017
- Full Text
- View/download PDF
13. Tumor cell dormancy
- Author
-
Gomis, Roger R. and Gawrzak, Sylwia
- Published
- 2017
- Full Text
- View/download PDF
14. Tumor-stroma interactions a trademark for metastasis
- Author
-
Morales, Monica, Planet, Evarist, Arnal-Estape, Anna, Pavlovic, Milica, Tarragona, Maria, and Gomis, Roger R.
- Published
- 2011
- Full Text
- View/download PDF
15. A FoxO-Smad Synexpression Group in Human Keratinocytes
- Author
-
Gomis, Roger R., Alarcón, Claudio, He, Wei, Wang, Qiongqing, Seoane, Joan, Lash, Alex, and Massagué, Joan
- Published
- 2006
- Full Text
- View/download PDF
16. RARRES3 suppresses breast cancer lung metastasis by regulating adhesion and differentiation
- Author
-
Morales, Mònica, Arenas, Enrique J, Urosevic, Jelena, Guiu, Marc, Fernández, Esther, Planet, Evarist, Fenwick, Robert Bryn, Fernández‐Ruiz, Sonia, Salvatella, Xavier, Reverter, David, Carracedo, Arkaitz, Massagué, Joan, and Gomis, Roger R
- Published
- 2014
- Full Text
- View/download PDF
17. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells
- Author
-
Celia-Terrassa, Toni, Meca-Cortes, Oscar, Mateo, Francesca, De Paz, Alexia Martinez, Rubio, Nuria, Arnal-Estape, Anna, Ell, Brian J., Bermudo, Raquel, Diaz, Alba, Guerra-Rebollo, Marta, Lozano, Juan Jose, Estaras, Conchi, Ulloa, Catalina, Alvarez-Simon, Daniel, Mila, Jordi, Vilella, Ramon, Paciucci, Rosanna, Martinez-Balbas, Marian, De Herreros, Antonio Garcia, Gomis, Roger R., Kang, Yibin, Blanco, Jeronimo, Fernondez, Pedro L., and Thomson, Timothy M.
- Subjects
Metastasis -- Research ,Stem cells -- Physiological aspects ,Epithelial tumors -- Research ,Cancer cells -- Research ,Health care industry - Abstract
Malignant progression in cancer requires populations of tumor-initiating cells (TICs) endowed with unlimited self renewal, survival under stress, and establishment of distant metastases. Additionally, the acquisition of invasive properties driven by epithelial-mesenchymal transition (EMT) is critical for the evolution of neoplastic cells into fully metastatic populations. Here, we characterize 2 human cellular models derived from prostate and bladder cancer cell lines to better understand the relationship between TIC and EMT programs in local invasiveness and distant metastasis. The model tumor subpopulations that expressed a strong epithelial gene program were enriched in highly metastatic TICs, while a second subpopulation with stable mesenchymal traits was impoverished in TICs. Constitutive overexpression of the transcription factor Snai1 in the epithelial/TIC-enriched populations engaged a mesenchymal gene program and suppressed their self renewal and metastatic phenotypes. Conversely, knockdown of EMT factors in the mesenchymal-like prostate cancer cell subpopulation caused a gain in epithelial features and properties of TICs. Both tumor cell subpopulations cooperated so that the nonmetastatic mesenchymal-like prostate cancer subpopulation enhanced the in vitro invasiveness of the metastatic epithelial subpopulation and, in vivo, promoted the escape of the latter from primary implantation sites and accelerated their metastatic colonization. Our models provide new insights into how dynamic interactions among epithelial, self-renewal, and mesenchymal gene programs determine the plasticity of epithelial TICs., Introduction There is a wealth of evidence that the acquisition of aggressive traits of cancer, or malignant progression, can be determined both by the occurrence of genetic mutations and by [...]
- Published
- 2012
- Full Text
- View/download PDF
18. Survival skills ensure that cancer spreads
- Author
-
Gomis, Roger R.
- Subjects
Survival after airplane accidents, shipwrecks, etc. -- Analysis ,Metastasis -- Analysis -- Control ,Tumor suppressor genes -- Influence ,Cell migration -- Analysis ,Cancer -- Development and progression -- Genetic aspects ,Environmental issues ,Science and technology ,Zoology and wildlife conservation - Abstract
How cancer cells migrate to a secondary site and become established there is not fully understood. An analysis of mouse and human cancer cells could help settle the debate about the role of the protein E-cadherin in this process. Expression of the protein E-cadherin aids the process of metastasis., Author(s): Roger R. Gomis Author Affiliations: Survival skills ensure that cancer spreads When cancer spreads from its primary site to become established at a secondary location, this process, termed metastasis, [...]
- Published
- 2019
- Full Text
- View/download PDF
19. Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice
- Author
-
Garcia, Marta, Velez, Roberto, Romagosa, Cleofé, Majem, Blanca, Pedrola, Núria, Olivan, Mireia, Rigau, Marina, Guiu, Marc, Gomis, Roger R., Morote, Juan, Reventós, Jaume, and Doll, Andreas
- Published
- 2014
- Full Text
- View/download PDF
20. Genes that mediate breast cancer metastasis to the brain
- Author
-
Bos, Paula D., Zhang, Xiang H.-F., Nadal, Cristina, Shu, Weiping, Gomis, Roger R., Nguyen, Don X., Minn, Andy J., van de Vijver, Marc J., Gerald, William L., Foekens, John A., and Massagué, Joan
- Published
- 2009
- Full Text
- View/download PDF
21. TGF[beta] Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4
- Author
-
Padua, David, Zhang, Xiang H.-F., Wang, Qiongqing, Nadal, Cristina, Gerald, William L., Gomis, Roger R., and Massague, Joan
- Subjects
Transforming growth factors ,Breast cancer ,Metastasis ,Biological sciences - Abstract
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.cell.2008.01.046 Byline: David Padua (1), Xiang H.-F. Zhang (1), Qiongqing Wang (1), Cristina Nadal (5), William L. Gerald (2), Roger R. Gomis (4), Joan Massague (1)(3) Keywords: HUMDISEASE; SIGNALING; CELLBIO Abstract: Cells released from primary tumors seed metastases to specific organs by a nonrandom process, implying the involvement of biologically selective mechanisms. Based on clinical, functional, and molecular evidence, we show that the cytokine TGF[beta] in the breast tumor microenvironment primes cancer cells for metastasis to the lungs. Central to this process is the induction of angiopoietin-like 4 (ANGPTL4) by TGF[beta] via the Smad signaling pathway. TGF[beta] induction of Angptl4 in cancer cells that are about to enter the circulation enhances their subsequent retention in the lungs, but not in the bone. Tumor cell-derived Angptl4 disrupts vascular endothelial cell-cell junctions, increases the permeability of lung capillaries, and facilitates the trans-endothelial passage of tumor cells. These results suggest a mechanism for metastasis whereby a cytokine in the primary tumor microenvironment induces the expression of another cytokine in departing tumor cells, empowering these cells to disrupt lung capillary walls and seed pulmonary metastases. Author Affiliation: (1) Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA (2) Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA (3) Howard Hughes Medical Institute, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA (4) Oncology Programme, Institute for Research in Biomedicine, 08028 Barcelona, Spain (5) Institut de Malalties Hemato-OncolA[sup.2]giques, Hospital Clinic-IDIBAPS, 08036 Barcelona, Spain Article History: Received 18 October 2007; Revised 11 December 2007; Accepted 30 January 2008 Article Note: (miscellaneous) Published: April 3, 2008
- Published
- 2008
22. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis
- Author
-
Gupta, Gaorav P., Nguyen, Don X., Chiang, Anne C., Bos, Paula D., Kim, Juliet Y., Nadal, Cristina, Gomis, Roger R., Manova-Todorova, Katia, and Massague, Joan
- Subjects
Environmental issues ,Science and technology ,Zoology and wildlife conservation - Abstract
Author(s): Gaorav P. Gupta [1, 5]; Don X. Nguyen [1, 5]; Anne C. Chiang [1, 2]; Paula D. Bos [1]; Juliet Y. Kim [1]; Cristina Nadal [1, 6]; Roger R. [...]
- Published
- 2007
- Full Text
- View/download PDF
23. Bridging the Gap in Biochemistry between Secondary School and University
- Author
-
Fernandez-Novell, Josep M., Gomis, Roger R., Cid, Emili, Barbera, Albert, and Guinovart, Joan J.
- Abstract
This manuscript describes a new strategy for introducing secondary school students to biochemistry. To bridge the gap between secondary education and the university, the Department of Biochemistry and Molecular Biology of the University of Barcelona, in collaboration with the SEBBM (The Spanish Society for Biochemistry and Molecular Biology), designed a course with lectures and practical classes for students in their last year of secondary school. The impact of this course on society has been considerable, and it is now a reference model for other disciplines. (Contains 2 tables.)
- Published
- 2002
- Full Text
- View/download PDF
24. C/EBPβ at the core of the TGFβ cytostatic response and its evasion in metastatic breast cancer cells
- Author
-
Gomis, Roger R., Alarcón, Claudio, Nadal, Cristina, Van Poznak, Catherine, and Massagué, Joan
- Published
- 2006
- Full Text
- View/download PDF
25. The logic of TGFβ signaling
- Author
-
Massagué, Joan and Gomis, Roger R.
- Published
- 2006
- Full Text
- View/download PDF
26. MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice.
- Author
-
Paterson, Alexander H G, Lucas, Peter C, Anderson, Stewart J, Mamounas, Eleftherios P, Brufsky, Adam, Baez-Diaz, Luis, King, Karen M, Lad, Thomas, Robidoux, André, Finnigan, Melanie, Sampayo, Miguel, Tercero, Juan Carlos, Mairet, Joël Jean, Wolff, Antonio C, Fehrenbacher, Louis, Wolmark, Norman, and Gomis, Roger R
- Subjects
BREAST cancer treatment ,ZOLEDRONIC acid ,ADJUVANT treatment of cancer - Abstract
Background The Adjuvant Zoledronic Acid (ZA) study in early breast cancer (AZURE) showed correlation between a nonamplified MAF gene in the primary tumor and benefit from adjuvant ZA. Adverse ZA outcomes occurred in MAF-amplified patients. NSABP B-34 is a validation study. Methods A retrospective analysis of MAF gene status in NSABP B-34 was performed. Eligible patients were randomly assigned to standard adjuvant systemic treatment plus 3 years oral clodronate (1600 mg/daily) or placebo. Tumors were tested for MAF gene amplification and analyzed for their relationship to clodronate for disease-free survival (DFS) and overall survival (OS) in MAF nonamplified patients. All statistical tests were 2-sided. Results MAF status was assessed in 2533 available primary tumor samples from 3311 patients. Of these, 37 withdrew consent; in 77 samples, no tumor was found; 536 assays did not meet quality standards, leaving 1883 (77.8%) evaluable for MAF assay by fluorescence in situ hybridization (947 from placebo and 936 from clodronate arms). At 5 years, in MAF nonamplified patients receiving clodronate, DFS improved by 30% (hazard ratio = 0.70, 95% confidence interval = 0.51 to 0.94; P = .02). OS improved at 5 years (hazard ratio = 0.59, 95% confidence interval = 0.37 to 0.93; P = .02) remaining statistically significant for clodronate throughout study follow-up. Conversely, adjuvant clodronate in women with MAF -amplified tumors was not associated with benefit but rather possible harm in some subgroups. Association between MAF status and menopausal status was not seen. Conclusions Nonamplified MAF showed statistically significant benefits (DFS and OS) with oral clodronate, supporting validation of the AZURE study. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. From latency to overt bone metastasis in breast cancer: potential for treatment and prevention.
- Author
-
Salvador, Fernando, Llorente, Alicia, and Gomis, Roger R
- Subjects
BONE metastasis ,METASTATIC breast cancer ,STERNUM ,STEM cell niches ,HEMATOPOIETIC stem cells - Abstract
Bone metastasis is present in a high percentage of breast cancer (BCa) patients with distant disease, especially in those with the estrogen receptor‐positive (ER+) subtype. Most cells that escape primary tumors are unable to establish metastatic lesions, which suggests that target organ microenvironments are hostile for tumor cells. This implies that BCa cells must achieve a process of speciation to adapt to the new conditions imposed in the new organ. Bone has unique characteristics that can be exploited by cancer cells: it undergoes constant remodeling and comprises diverse environments (including osteogenic, perivascular, and hematopoietic stem cell niches). This allows colonizing cells to take advantage of numerous adhesion molecules, matrix proteins, and soluble factors that facilitate homing, survival, and, eventually, metastatic outgrowth. However, in most cases, metastatic lesions enter into a latency state that can last months, years, or even decades, before forming a clinically detectable macrometastasis. This dormant state challenges the effectiveness of adjuvant chemotherapy. Detecting which tumors are more prone to metastasize to bone and developing new specific therapies that target bone metastasis represent urgent clinical needs. Here, we review the biological mechanisms of BCa bone metastasis and provide the latest options of treatments and predictive markers that are currently in clinical use or are being tested in clinical assays. © 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
28. Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer.
- Author
-
Cejalvo, Juan Miguel, Pascual, Tomás, Fernández-Martínez, Aranzazu, Brasó-Maristany, Fara, Gomis, Roger R., Perou, Charles M., Muñoz, Montserrat, and Prat, Aleix
- Abstract
Gene expression profiling has had a considerable impact on our understanding ofbreastcancer biology. Duringthelast decade, 4 intrinsic molecular subtypes of breast cancer (Luminal A, Luminal B, HER2-enriched [HER2-E] and Basal-like) have been identified and intensively studied. In this article, we review and discuss the clinical implications of the 2 non-luminal subtypes (i.e. HER2-E and Basal-like) identified within hormone receptor (HR)-positive disease. After reviewing 32 studies for a total of 13,091 samples, ∼8% and ∼ 15% of early and metastatic HR+/HER2-negative breast cancer, respectively, were found to be non-luminal. Clinically, HR+/HER2-negative/non-luminal subtypes have been associated with estrogen independence, chemo-sensitivity, resistance to CDK4/6 inhibition and poor outcome. Interestingly, EGFR/HER2 tyrosine kinase inhibition might be of value in the HR+/HER2-negative/HER2-E subtype. Finally, the HER2-E subtype within HR+/HER2 + disease represents ∼ 30% and has been associated with anti-HER2 sensitivity, chemo-sensitivity and resistance to CDK4/6 inhibition. In the upcoming years, retrospective and prospective clinical trials evaluating both biomarkers should lead to improvements in patient outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
29. EPCR promotes breast cancer progression by altering SPOCK1/testican 1-mediated 3D growth.
- Author
-
Perurena, Naiara, Zandueta, Carolina, Martínez-Canarias, Susana, Moreno, Haritz, Vicent, Silvestre, Almeida, Ana S., Guruceaga, Elisabet, Gomis, Roger R., Santisteban, Marta, Egeblad, Mikala, Hermida, José, and Lecanda, Fernando
- Subjects
PROTEIN C ,ANTICOAGULANTS ,CYTOPROTECTION ,CANCER invasiveness ,PROTEOGLYCANS - Abstract
Background: Activated protein C/endothelial protein C receptor (APC/EPCR) axis is physiologically involved in anticoagulant and cytoprotective activities in endothelial cells. Emerging evidence indicates that EPCR also plays a role in breast stemness and human tumorigenesis. Yet, its contribution to breast cancer progression and metastasis has not been elucidated. Methods: Transcriptomic status of EPCR was examined in a cohort of 286 breast cancer patients. Cell growth kinetics was evaluated in control and EPCR and SPARC/osteonectin, Cwcv, and kazal-like domains proteoglycan (SPOCK1/testican 1) silenced breast cancer cells in 2D, 3D, and in co-culture conditions. Orthotopic tumor growth and lung and osseous metastases were evaluated in several human and murine xenograft breast cancer models. Tumor-stroma interactions were further studied in vivo by immunohistochemistry and flow cytometry. An EPCRinduced gene signature was identified by microarray analysis. Results: Analysis of a cohort of breast cancer patients revealed an association of high EPCR levels with adverse clinical outcome. Interestingly, EPCR knockdown did not affect cell growth kinetics in 2D but significantly reduced cell growth in 3D cultures. Using several human and murine xenograft breast cancer models, we showed that EPCR silencing reduced primary tumor growth and secondary outgrowths at metastatic sites, including the skeleton and the lungs. Interestingly, these effects were independent of APC ligand stimulation in vitro and in vivo. Transcriptomic analysis of EPCR-silenced tumors unveiled an effect mediated by matricellular secreted proteoglycan SPOCK1/testican 1. Interestingly, SPOCK1 silencing suppressed in vitro 3D growth. Moreover, SPOCK1 ablation severely decreased orthotopic tumor growth and reduced bone metastatic osteolytic tumors. High SPOCK1 levels were also associated with poor clinical outcome in a subset breast cancer patients. Our results suggest that EPCR through SPOCK1 confers a cell growth advantage in 3D promoting breast tumorigenesis and metastasis. Conclusions: EPCR represents a clinically relevant factor associated with poor outcome and a novel vulnerability to develop combination therapies for breast cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
30. Tumour stroma-derived lipocalin-2 promotes breast cancer metastasis.
- Author
-
Ören, Bilge, Urosevic, Jelena, Mertens, Christina, Mora, Javier, Guiu, Marc, Gomis, Roger R, Weigert, Andreas, Schmid, Tobias, Grein, Stephan, Brüne, Bernhard, and Jung, Michaela
- Abstract
Tumour cell-secreted factors skew infiltrating immune cells towards a tumour-supporting phenotype, expressing pro-tumourigenic mediators. However, the influence of lipocalin-2 (Lcn2) on the metastatic cascade in the tumour micro-environment is still not clearly defined. Here, we explored the role of stroma-derived, especially macrophage-released, Lcn2 in breast cancer progression. Knockdown studies and neutralizing antibody approaches showed that Lcn2 contributes to the early events of metastasis in vitro. The release of Lcn2 from macrophages induced an epithelial-mesenchymal transition programme in MCF-7 breast cancer cells and enhanced local migration as well as invasion into the extracellular matrix, using a three-dimensioanl ( 3D) spheroid model. Moreover, a global Lcn2 deficiency attenuated breast cancer metastasis in both the MMTV-PyMT breast cancer model and a xenograft model inoculating MCF-7 cells pretreated with supernatants from wild-type and Lcn2-knockdown macrophages. To dissect the role of stroma-derived Lcn2, we employed an orthotopic mammary tumour mouse model. Implantation of wild-type PyMT tumour cells into Lcn2-deficient mice left primary mammary tumour formation unaltered, but specifically reduced tumour cell dissemination into the lung. We conclude that stroma-secreted Lcn2 promotes metastasis in vitro and in vivo, thereby contributing to tumour progression. Our study highlights the tumourigenic potential of stroma-released Lcn2 and suggests Lcn2 as a putative therapeutic target. Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
31. MiniAp-4: AVenom-Inspired Peptidomimetic for Brain Delivery.
- Author
-
Oller‐Salvia, Benjamí, Sánchez‐Navarro, Macarena, Ciudad, Sonia, Guiu, Marc, Arranz‐Gibert, Pol, Garcia, Cristina, Gomis, Roger R., Cecchelli, Roméo, García, Jesús, Giralt, Ernest, and Teixidó, Meritxell
- Subjects
DRUG delivery systems ,BLOOD-brain barrier ,CENTRAL nervous system diseases ,THERAPEUTICS ,PEPTIDES ,APAMIN ,LABORATORY mice - Abstract
Drug delivery across the blood-brain barrier (BBB) is a formidable challenge for therapies targeting the central nervous system. Although BBB shuttle peptides enhance transport into the brain non-invasively, their application is partly limited by lability to proteases. The present study proposes the use of cyclic peptides derived from venoms as an affordable way to circumvent this drawback. Apamin, a neurotoxin from bee venom, was minimized by reducing its complexity, toxicity, and immunogenicity, while preserving brain targeting, active transport, and protease resistance. Among the analogues designed, the monocyclic lactambridged peptidomimetic MiniAp-4 was the most permeable. This molecule is capable of translocating proteins and nanoparticles in a human-cell-based BBB model. Furthermore, MiniAp-4 can efficiently deliver a cargo across the BBB into the brain parenchyma of mice. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
32. MiniAp-4: A Venom-Inspired Peptidomimetic for Brain Delivery.
- Author
-
Oller ‐ Salvia, Benjamí, Sánchez ‐ Navarro, Macarena, Ciudad, Sonia, Guiu, Marc, Arranz ‐ Gibert, Pol, Garcia, Cristina, Gomis, Roger R., Cecchelli, Roméo, García, Jesús, Giralt, Ernest, and Teixidó, Meritxell
- Subjects
DRUG delivery systems ,BLOOD-brain barrier ,CENTRAL nervous system ,PHYSIOLOGICAL effects of venom ,PROTEASE inhibitors - Abstract
Drug delivery across the blood-brain barrier (BBB) is a formidable challenge for therapies targeting the central nervous system. Although BBB shuttle peptides enhance transport into the brain non-invasively, their application is partly limited by lability to proteases. The present study proposes the use of cyclic peptides derived from venoms as an affordable way to circumvent this drawback. Apamin, a neurotoxin from bee venom, was minimized by reducing its complexity, toxicity, and immunogenicity, while preserving brain targeting, active transport, and protease resistance. Among the analogues designed, the monocyclic lactambridged peptidomimetic MiniAp-4 was the most permeable. This molecule is capable of translocating proteins and nanoparticles in a human-cell-based BBB model. Furthermore, MiniAp-4 can efficiently deliver a cargo across the BBB into the brain parenchyma of mice. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
33. Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis.
- Author
-
Pavlovic, Milica, Arnal-Estapé, Anna, Rojo, Federico, Bellmunt, Anna, Tarragona, Maria, Guiu, Marc, Planet, Evarist, Garcia-Albéniz, Xabier, Morales, Mónica, Urosevic, Jelena, Gawrzak, Sylwia, Rovira, Ana, Prat, Aleix, Nonell, Lara, Lluch, Ana, Jean-Mairet, Joël, Coleman, Robert, Albanell, Joan, and Gomis, Roger R.
- Subjects
METASTASIS ,RISK of metastasis ,BONE tumors ,ANIMAL experimentation ,ANIMALS ,BIOCHEMISTRY ,BIOLOGICAL models ,BREAST tumors ,CELL lines ,GENES ,IMMUNOHISTOCHEMISTRY ,PHENOMENOLOGY ,MICE ,ONCOGENES ,PROGNOSIS ,XENOGRAFTS ,FLUORESCENCE in situ hybridization ,PREDICTIVE tests ,DISEASE incidence ,PROPORTIONAL hazards models ,IN vitro studies ,ODDS ratio ,IN vivo studies ,GENETICS ,TUMOR risk factors - Abstract
Background: There are currently no biomarkers for early breast cancer patient populations at risk of bone metastasis. Identification of mediators of bone metastasis could be of clinical interest.Methods: A de novo unbiased screening approach based on selection of highly bone metastatic breast cancer cells in vivo was used to determine copy number aberrations (CNAs) associated with bone metastasis. The CNAs associated with bone metastasis were examined in independent primary breast cancer datasets with annotated clinical follow-up. The MAF gene encoded within the CNA associated with bone metastasis was subjected to gain and loss of function validation in breast cancer cells (MCF7, T47D, ZR-75, and 4T1), its downstream mechanism validated, and tested in clinical samples. A multivariable Cox cause-specific hazard model with competing events (death) was used to test the association between 16q23 or MAF and bone metastasis. All statistical tests were two-sided.Results: 16q23 gain CNA encoding the transcription factor MAF mediates breast cancer bone metastasis through the control of PTHrP. 16q23 gain (hazard ratio (HR) for bone metastasis = 14.5, 95% confidence interval (CI) = 6.4 to 32.9, P < .001) as well as MAF overexpression (HR for bone metastasis = 2.5, 95% CI = 1.7 to 3.8, P < .001) in primary breast tumors were specifically associated with risk of metastasis to bone but not to other organs.Conclusions: These results suggest that MAF is a mediator of breast cancer bone metastasis. 16q23 gain or MAF protein overexpression in tumors may help to select patients at risk of bone relapse. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
34. CLK2 blockade modulates alternative splicing compromising MYC‐driven breast tumors.
- Author
-
Salvador, Fernando and Gomis, Roger R.
- Abstract
MYC oncogene overexpression/amplification is common in multiple human cancers, in which it regulates proliferation, apoptosis and cell metabolism, among other processes, and its expression associates with poor prognosis. Targeting MYC presents an exciting therapeutic possibility, but developing appropriate drugs that impair protein function remains challenging. Searching for alternative therapeutic options for treating aggressive MYC‐driven cancers is thus of high clinical interest. Intriguingly, MYC‐driven cancers present vulnerability against spliceosome inhibition. In this issue of EMBO Molecular Medicine, Iwai et al ( ) tackle targeting the splicing regulatory Cdc2‐like kinase (CLKs) family. They report that a novel, orally administered CLK2 inhibitor (T‐025) induces exon skipping, which results in cancer cell growth reduction, especially in breast cancer (BCa) MYC‐driven tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
35. Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH.
- Author
-
Urosevic, Jelena, Garcia-Albéniz, Xabier, Planet, Evarist, Real, Sebastián, Céspedes, María Virtudes, Guiu, Marc, Fernandez, Esther, Bellmunt, Anna, Gawrzak, Sylwia, Pavlovic, Milica, Mangues, Ramon, Dolado, Ignacio, Barriga, Francisco M., Nadal, Cristina, Kemeny, Nancy, Batlle, Eduard, Nebreda, Angel R., and Gomis, Roger R.
- Subjects
COLON cancer ,CANCER cells ,LIVER metastasis ,MITOGEN-activated protein kinases ,LABORATORY mice - Abstract
The mechanisms that allow colon cancer cells to form liver and lung metastases, and whether KRAS mutation influences where and when metastasis occurs, are unknown. We provide clinical and molecular evidence showing that different MAPK signalling pathways are implicated in this process. Whereas ERK2 activation provides colon cancer cells with the ability to seed and colonize the liver, reduced p38 MAPK signalling endows cancer cells with the ability to form lung metastasis from previously established liver lesions. Downregulation of p38 MAPK signalling results in increased expression of the cytokine PTHLH, which contributes to colon cancer cell extravasation to the lung by inducing caspase-independent death in endothelial cells of the lung microvasculature. The concerted acquisition of metastatic traits in the colon cancer cells together with the sequential colonization of liver and lung highlights the importance of metastatic lesions as a platform for further dissemination. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
36. Inhibition of Specific NF-κB Activity Contributes to the Tumor Suppressor Function of 14-3-3δ in Breast Cancer.
- Author
-
Inglés-Esteve, Julia, Morales, Mónica, Dalmases, Alba, Garcia-Carbonell, Ricard, Jené-S, Alba, pez-Bigas, Núria ó, Iglesias, Mar, Ruiz-Herguido, Cristina, Rovira, Ana, Rojo, Federico, Albanell, Joan, Gomis, Roger R., Bigas, Anna, and Espinosa, Lluís
- Subjects
TUMOR suppressor genes ,BREAST cancer ,METHYLATION ,TUMOR necrosis factors ,METASTASIS ,CANCER prognosis - Abstract
14-3-3δ is frequently lost in human breast cancers by genetic deletion or promoter methylation. We have now investigated the involvement of 14-3-3δ in the termination of NF-κB signal in mammary cells and its putative role in cancer relapse and metastasis. Our results show that 14-3-3s regulates nuclear export of p65-NF-κB following chronic TNFa stimulation. Restoration of 14-3-3δ in breast cancer cells reduces migration capacity and metastatic abilities in vivo. By microarray analysis, we have identified a genetic signature that responds to TNFa in a 14-3-3δ-dependent manner and significantly associates with different breast and other types of cancer. By interrogating public databases, we have found that overexpression of this signature correlates with poor relapse-free survival in breast cancer patients. Finally, screening of 96 human breast tumors showed that NF-κB activation strictly correlates with the absence of 14-3-3δ and it is significantly associated with worse prognosis in the multivariate analysis. Our findings identify a genetic signature that is important for breast cancer prognosis and for future personalized treatments based on NF-κB targeting [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
37. Accurate Expression Profiling of Very Small Cell Populations.
- Author
-
Gonzalez-Roca, Eva, Garcia-Albéniz, Xabier, Rodriguez-Mulero, Silvia, Gomis, Roger R., Kornacker, Karl, and Auer, Herbert
- Subjects
GENE expression ,RNA ,GENETIC transcription ,CELL populations ,CELL proliferation ,PHYSIOLOGY ,NUCLEIC acids ,ANTISENSE nucleic acids ,CYTOLOGY - Abstract
Background: Expression profiling, the measurement of all transcripts of a cell or tissue type, is currently the most comprehensive method to describe their physiological states. Given that accurate profiling methods currently available require RNA amounts found in thousands to millions of cells, many fields of biology working with specialized cell types cannot use these techniques because available cell numbers are limited. Currently available alternative methods for expression profiling from nanograms of RNA or from very small cell populations lack a broad validation of results to provide accurate information about the measured transcripts. Methods and Findings: We provide evidence that currently available methods for expression profiling of very small cell populations are prone to technical noise and therefore cannot be used efficiently as discovery tools. Furthermore, we present Pico Profiling, a new expression profiling method from as few as ten cells, and we show that this approach is as informative as standard techniques from thousands to millions of cells. The central component of Pico Profiling is Whole Transcriptome Amplification (WTA), which generates expression profiles that are highly comparable to those produced by others, at different times, by standard protocols or by Real-time PCR. We provide a complete workflow from RNA isolation to analysis of expression profiles. Conclusions: Pico Profiling, as presented here, allows generating an accurate expression profile from cell populations as small as ten cells. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
38. Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples.
- Author
-
Olivan, Mireia, Garcia, Marta, Suárez, Leticia, Guiu, Marc, Gros, Laura, Méndez, Olga, Rigau, Marina, Reventós, Jaume, Segura, Miguel F., de Torres, Inés, Planas, Jacques, de la Cruz, Xavier, Gomis, Roger R., Morote, Juan, Rodríguez-Barrueco, Ruth, and Santamaria, Anna
- Subjects
ANIMAL experimentation ,BLOOD plasma ,MICRORNA ,BONE metastasis ,DESCRIPTIVE statistics ,CELL lines ,PROSTATE tumors ,MICE - Abstract
Simple Summary: Prostate cancer (PCa) is the most prevalent cancer in males worldwide, and it was the fifth leading cause of cancer mortality in this group in 2020. Near 70% of advanced-stage PCa patients will undergo bone metastasis, suffering pathological complications that severely affect patients' quality of life and probably progress in most cases to lethal PCa. Our main objective was to unveil novel molecules associated with choosing the bone as a metastatic niche. For this purpose, we generated and characterized a cell line with increased tropism to bone. Its molecular analysis has led us to identify factors with a potential role in bone metastasis that could also be used as biomarkers of disease progression. These data help us to understand the mechanisms that increase bone metastasis penetrance of PCa cells and could provide new therapeutic tools in the future for patients with worse prognoses. About 70% of advanced-stage prostate cancer (PCa) patients will experience bone metastasis, which severely affects patients' quality of life and progresses to lethal PCa in most cases. Hence, understanding the molecular heterogeneity of PCa cell populations and the signaling pathways associated with bone tropism is crucial. For this purpose, we generated an animal model with high penetrance to metastasize to bone using an intracardiac percutaneous injection of PC3 cells to identify PCa metastasis-promoting factors. Using genomic high-throughput analysis we identified a miRNA signature involved in bone metastasis that also presents potential as a biomarker of PCa progression in human samples. In particular, the downregulation of miR-135b favored the incidence of bone metastases by significantly increasing PCa cells' migratory capacity. Moreover, the PLAG1, JAKMIP2, PDGFA, and VTI1b target genes were identified as potential mediators of miR-135b's role in the dissemination to bone. In this study, we provide a genomic signature involved in PCa bone growth, contributing to a better understanding of the mechanisms responsible for this process. In the future, our results could ultimately translate into promising new therapeutic targets for the treatment of lethal PCa. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
39. Control of glycogen deposition
- Author
-
Ferrer, Juan C., Favre, Cristián, Gomis, Roger R., Fernández-Novell, Josep M., García-Rocha, Mar, de la Iglesia, Núria, Cid, Emili, and Guinovart, Joan J.
- Subjects
GLUCOSE-6-phosphatase ,GLYCOGEN synthesis - Abstract
Traditionally, glycogen synthase (GS) has been considered to catalyze the key step of glycogen synthesis and to exercise most of the control over this metabolic pathway. However, recent advances have shown that other factors must be considered. Moreover, the control of glycogen deposition does not follow identical mechanisms in muscle and liver. Glucose must be phosphorylated to promote activation of GS. Glucose-6-phosphate (Glc-6-P) binds to GS, causing the allosteric activation of the enzyme probably through a conformational rearrangement that simultaneously converts it into a better substrate for protein phosphatases, which can then lead to the covalent activation of GS. The potency of Glc-6-P for activation of liver GS is determined by its source, since Glc-6-P arising from the catalytic action of glucokinase (GK) is much more effective in mediating the activation of the enzyme than the same metabolite produced by hexokinase I (HK I). As a result, hepatic glycogen deposition from glucose is subject to a system of control in which the ‘controller’, GS, is in turn controlled by GK. In contrast, in skeletal muscle, the control of glycogen synthesis is shared between glucose transport and GS. The characteristics of the two pairs of isoenzymes, liver GS/GK and muscle GS/HK I, and the relationships that they establish are tailored to suit specific metabolic roles of the tissues in which they are expressed. The key enzymes in glycogen metabolism change their intracellular localization in response to glucose. The changes in the intracellular distribution of liver GS and GK triggered by glucose correlate with stimulation of glycogen synthesis. The translocation of GS, which constitutes an additional mechanism of control, causes the orderly deposition of hepatic glycogen and probably represents a functional advantage in the metabolism of the polysaccharide. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
40. Glucose 6-Phosphate Produced by Gluconeogenesis and by Glucokinase Is Equally Effective in Activating Hepatic Glycogen Synthase.
- Author
-
Gomis, Roger R., Favre, Cristian, García-Rocha, Mar, Fernández-Novell, Josep M., Ferrer, Juan C., and Guinovart, Joan J.
- Subjects
- *
GLUCONEOGENESIS , *LIVER cells - Abstract
Cites the production of glucose 6-phosphate by gluconeogenesis. Activation of hepatic glycogen synthase; Increase in glycogen accumulation; Incubation of cultured hepatocytes.
- Published
- 2003
- Full Text
- View/download PDF
41. Cysteine and Folate Metabolism Are Targetable Vulnerabilities of Metastatic Colorectal Cancer.
- Author
-
Tarragó-Celada, Josep, Foguet, Carles, Tarrado-Castellarnau, Míriam, Marin, Silvia, Hernández-Alias, Xavier, Perarnau, Jordi, Morrish, Fionnuala, Hockenbery, David, Gomis, Roger R., Ruppin, Eytan, Yuneva, Mariia, Atauri, Pedro de, and Cascante, Marta
- Subjects
CYSTEINE metabolism ,FOLIC acid metabolism ,ADENOCARCINOMA ,CELL lines ,COLON tumors ,METASTASIS ,RECTUM tumors ,PSYCHOLOGICAL vulnerability - Abstract
Simple Summary: In this work, we studied the metabolic reprogramming of same-patient-derived cell lines with increasing metastatic potential to develop new therapeutic approaches against metastatic colorectal cancer. Using a novel systems biology approach to integrate multiple layers of omics data, we predicted and validated that cystine uptake and folate metabolism, two key pathways related to redox metabolism, are potential targets against metastatic colorectal cancer. Our findings indicate that metastatic cell lines are selectively dependent on redox homeostasis, paving the way for new targeted therapies. With most cancer-related deaths resulting from metastasis, the development of new therapeutic approaches against metastatic colorectal cancer (mCRC) is essential to increasing patient survival. The metabolic adaptations that support mCRC remain undefined and their elucidation is crucial to identify potential therapeutic targets. Here, we employed a strategy for the rational identification of targetable metabolic vulnerabilities. This strategy involved first a thorough metabolic characterisation of same-patient-derived cell lines from primary colon adenocarcinoma (SW480), its lymph node metastasis (SW620) and a liver metastatic derivative (SW620-LiM2), and second, using a novel multi-omics integration workflow, identification of metabolic vulnerabilities specific to the metastatic cell lines. We discovered that the metastatic cell lines are selectively vulnerable to the inhibition of cystine import and folate metabolism, two key pathways in redox homeostasis. Specifically, we identified the system xCT and MTHFD1 genes as potential therapeutic targets, both individually and combined, for combating mCRC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
42. Organ-specific metastases.
- Author
-
Urosevic, Jelena and Gomis, Roger R.
- Published
- 2018
- Full Text
- View/download PDF
43. Regulation of death receptor signaling by the autophagy protein TP53INP2.
- Author
-
Ivanova, Saška, Polajnar, Mira, Narbona‐Perez, Alvaro Jesus, Hernandez‐Alvarez, Maria Isabel, Frager, Petra, Slobodnyuk, Konstantin, Plana, Natalia, Nebreda, Angel R, Palacin, Manuel, Gomis, Roger R, Behrends, Christian, and Zorzano, Antonio
- Subjects
DEATH receptors ,UBIQUITINATION ,CELL receptors ,LIVER cells ,CANCER cells ,CELL death - Abstract
TP53INP2 positively regulates autophagy by binding to Atg8 proteins. Here, we uncover a novel role of TP53INP2 in death‐receptor signaling. TP53INP2 sensitizes cells to apoptosis induced by death receptor ligands. In keeping with this, TP53INP2 deficiency in cultured cells or mouse livers protects against death receptor‐induced apoptosis. TP53INP2 binds caspase‐8 and the ubiquitin ligase TRAF6, thereby promoting the ubiquitination and activation of caspase‐8 by TRAF6. We have defined a TRAF6‐interacting motif (TIM) and a ubiquitin‐interacting motif in TP53INP2, enabling it to function as a scaffold bridging already ubiquitinated caspase‐8 to TRAF6 for further polyubiquitination of caspase‐8. Mutations of key TIM residues in TP53INP2 abrogate its interaction with TRAF6 and caspase‐8, and subsequently reduce levels of death receptor‐induced apoptosis. A screen of cancer cell lines showed that those with higher protein levels of TP53INP2 are more prone to TRAIL‐induced apoptosis, making TP53INP2 a potential predictive marker of cancer cell responsiveness to TRAIL treatment. These findings uncover a novel mechanism for the regulation of caspase‐8 ubiquitination and reveal TP53INP2 as an important regulator of the death receptor pathway. Synopsis: Death cell receptors initiate apoptosis, necroptosis or inflammation depending on their cell‐surface expression, ligand concentration and intracellular context. The autophagy regulator TP53INP2 promotes death receptor‐induced apoptosis through TRAF6‐dependent ubiquitination of caspase‐8. TP53INP2 sensitizes cancer cells to death receptor‐induced apoptosis.Knockout of TP53INP2 protects cultured cells and mouse livers from FasL‐induced apoptosis.TP53INP2 binds TRAF6 E3 ligase and ubiquitinated caspase‐8 via its TRAF6‐ and ubiquitin‐interacting motifs, respectively, to enhance caspase‐8 poly‐ubiquitination.High TP53INP2 levels may predict responsiveness of cancer cells to TRAIL treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
44. MAPK signaling control of colon cancer metastasis.
- Author
-
Urosevic, Jelena, Nebreda, Angel R., and Gomis, Roger R.
- Published
- 2014
- Full Text
- View/download PDF
45. FoxA and LIPG endothelial lipase control the uptake of extracellular lipids for breast cancer growth.
- Author
-
Slebe, Felipe, Rojo, Federico, Vinaixa, Maria, García-Rocha, Mar, Testoni, Giorgia, Guiu, Marc, Planet, Evarist, Samino, Sara, Arenas, Enrique J., Beltran, Antoni, Rovira, Ana, Lluch, Ana, Salvatella, Xavier, Yanes, Oscar, Albanell, Joan, Guinovart, Joan J., and Gomis, Roger R.
- Published
- 2016
- Full Text
- View/download PDF
46. Tissue-specific metastases.
- Author
-
Pavlovic, Milica, Arnal, Anna, Tarragona, Maria, Morales, Monica, and Gomis, Roger R.
- Published
- 2011
- Full Text
- View/download PDF
47. The RNA binding protein CPEB2 regulates hormone sensing in mammary gland development and luminal breast cancer.
- Author
-
Pascual, Rosa, Martín, Judit, Salvador, Fernando, Reina, Oscar, Chanes, Veronica, Millanes-Romero, Alba, Suñer, Clara, Fernández-Miranda, Gonzalo, Bartomeu, Anna, Yi-Shuian Huang, Gomis, Roger R., and Méndez, Raúl
- Subjects
- *
RNA-binding proteins , *MAMMARY glands , *PROGESTERONE receptors , *PROLACTIN , *BREAST cancer , *MEDICAL sciences , *DEVELOPMENTAL biology - Abstract
The article offers information on the role of RNA binding protein CPEB2 in regulating hormone sensing in mammary gland development and luminal breast cancer. It mentions the study of the hierarchical networks of transcription factors driving mammary gland development and function. It discusses the process of organogenesis, directed by coordinated cell proliferation and differentiation programs.
- Published
- 2020
- Full Text
- View/download PDF
48. Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.
- Author
-
Coleman, Robert, Hall, Andrew, Albanell, Joan, Hanby, Andrew, Bell, Richard, Cameron, David, Dodwell, David, Marshall, Helen, Jean-Mairet, Joël, Tercero, Juan-Carlos, Rojo, Federico, Gregory, Walter, and Gomis, Roger R
- Subjects
- *
BONE metastasis , *ADJUVANT treatment of cancer , *BREAST cancer diagnosis , *CANCER relapse , *DIPHOSPHONATES , *ZOLEDRONIC acid , *RANDOMIZED controlled trials , *THERAPEUTICS , *ANTINEOPLASTIC agents , *BREAST tumors , *CANCER invasiveness , *COMBINED modality therapy , *COMPARATIVE studies , *DRUG administration , *DRUG dosage , *DOSE-effect relationship in pharmacology , *DRUG toxicity , *IMIDAZOLES , *LONGITUDINAL method , *MASTECTOMY , *RESEARCH methodology , *MEDICAL cooperation , *PROGNOSIS , *PROTEINS , *RESEARCH , *SURVIVAL analysis (Biometry) , *TUMOR classification , *EVALUATION research , *TREATMENT effectiveness , *PROPORTIONAL hazards models , *KAPLAN-Meier estimator - Abstract
Background: Adjuvant use of bisphosphonates can reduce the incidence of bone metastases in early breast cancer. Recurrence and survival seem to be improved only in postmenopausal patients, but the underlying mechanisms remain unclear. We investigated whether MAF amplification (a biomarker for bone metastasis) in primary tumours could predict the treatment outcomes of adjuvant zoledronic acid.Methods: The study population included patients enrolled in the international, open-label, randomised, controlled, phase 3 AZURE trial at eligible UK sites who had stage II or III breast cancer and who gave consent for use of their primary tumour samples. Patients were randomly assigned (1:1) to receive standard adjuvant systemic therapy alone (control group) or with zoledronic acid every 3-4 weeks for six doses, then every 3-6 months until the end of 5 years. Minimisation took into account the number of involved axillary lymph nodes, clinical tumour stage, oestrogen-receptor status, type and timing of systemic therapy, menopausal status, statin use, and treating centre. The primary endpoint was disease-free survival; the secondary endpoint, invasive-disease-free survival, was the primary disease endpoint for the analysis in this report. MAF amplification was assessed by fluorescence in-situ hybridisation of two cores of breast tumour tissue in a microarray, done in a central laboratory by technicians unaware of treatment assignment. We used multivariate analyses to assess disease outcomes by intention to treat. We also assessed interactions between MAF-positive status and menopausal status on efficacy of zoledronic acid. The AZURE trial is registered with the International Standard Randomised Controlled Trial Registry, number ISRCTN79831382.Findings: 1739 AZURE patients contributed primary tumour samples, of whom 865 (50%) had two assessable cores (445 in the control groups and 420 in the zoledronic acid group). 184 (21%) tumours were MAF positive (85 in the control groups and 99 in the zoledronic acid group) and the remaining tumours were MAF negative. At a median follow-up of 84·6 months (IQR 72·0-95·8), MAF status was not prognostic for invasive-disease-free survival in the control group (MAF-positive vs MAF-negative: hazard ratio [HR] 0·92, 95% CI 0·59-1·41), but was in the zoledronic acid group (0·52, 0·36-0·75). In patients with MAF-negative tumours, zoledronic acid was associated with higher invasive-disease-free survival than was control treatment (HR 0·74, 95% CI 0·56-0·98), but not in patients who had MAF-positive tumours. Additionally, among 121 patients not postmenopausal at randomisation with MAF-positive tumours, zoledronic acid was associated with lower invasive-disease-free survival (HR 2·47, 95% CI 1·23-4·97) and overall survival (2·27, 95% CI 1·04-4·93) than control treatment.Interpretation: MAF status can predict likelihood of benefit from adjuvant zoledronic acid and merits further investigation as a potential companion diagnostic.Funding: Novartis Global and Inbiomotion. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
49. Constitutive HER2 Signaling Promotes Breast Cancer Metastasis through Cellular Senescence.
- Author
-
Angelini, Pier Davide, Fluck, Mariano F. Zacarias, Pedersen, Kim, Parra-Palau, Josep Lluís, Guiu, Marc, Morales, Cristina Bernado, Vicario, Rocio, Luque-García, Antonio, Navalpotro, Nerea Peiro, Giralt, Jordi, Canals, Francesc, Gomis, Roger R., Tabernero, Josep, Baselga, Jose, Villanueva, Josep, and Arribas, Joaquín
- Subjects
- *
BREAST cancer , *CANCER invasiveness , *METASTASIS , *ONCOGENES , *EPITHELIAL cells , *CELLULAR aging - Abstract
Senescence, a terminal cell proliferation arrest, can be triggered by oncogenes. Oncogene-induced senescence is classically considered a tumor defense barrier. However, several findings show that, under certain circumstances, senescent cells may favor tumor progression because of their secretory phenotype. Here, we show that the expression in different breast epithelial cell lines of p95HER2, a constitutively active fragment of the tyrosine kinase receptor HER2, results in either increased proliferation or senescence. In senescent cells, p95HER2 elicits a secretome enriched in proteases, cytokines, and growth factors. This secretory phenotype is not a mere consequence of the senescence status and requires continuous HER2 signaling to be maintained. Underscoring the functional relevance of the p95HER2-induced senescence secretome, we show that p95HER2-induced senescent cells promote metastasis in vivo in a non-cell-autonomous manner. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
50. Identification of NOG as a Specific Breast Cancer Bone Metastasis-supporting Gene.
- Author
-
Tarragona, Maria, Pavlovic, Milica, Arnal-Estapé, Anna, Urosevic, Jelena, Morales, Mònica, Guiu, Marc, Planet, Evarist, González-Suárez, Eva, and Gomis, Roger R.
- Subjects
- *
BONE metastasis , *BREAST cancer , *CANCER cells , *BIOLOGICAL systems , *OSTEOCLASTS , *CELL differentiation , *GENETICS - Abstract
Metastasis requires numerous biological functions that jointly provide tumor cells from a primary site to seed and colonize a distant organ. Some of these activities are selected for in the primary site, whereas others are acquired at the metastatic niche. We provide molecular evidence showing that the BMP inhibitor, NOG, provides metastatic breast cancer cells with the ability to colonize the bone. NOG expression is acquired during the late events of metastasis, once cells have departed from the primary site, because it is not enriched in primary tumors with high risk of bone relapse. On the contrary, breast cancer bone metastatic lesions do select for high levels of NOG expression when compared with metastasis to the lung, liver, and brain. Pivotal to the bone colonization functions is the contribution of NOG to metastatic autonomous and nonautonomous cell functions. Using genetic approaches, we show that when NOG is expressed in human breast cancer cells, it facilitates bone colonization by fostering osteoclast differentiation and bone degradation and also contributes to metastatic lesions reinitiation. These findings reveal how aggressive cancer cell autonomous and nonautonomous functions can be mechanistically coupled to greater bone metastatic potential. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.